key: cord-0977672-gwy6qpxm
authors: Gaston, David C.; Malinis, Maricar; Osborn, Rebecca; Peaper, David R.; Landry, Marie; Juthani‐Mehta, Manisha; Azar, Marwan M.
title: Clinical implications of SARS‐CoV‐2 cycle threshold values in solid organ transplant recipients
date: 2020-10-31
journal: Am J Transplant
DOI: 10.1111/ajt.16357
sha: 02e4efbf7a4b8d5b5e980c4e7a7433ad78e7a0ba
doc_id: 977672
cord_uid: gwy6qpxm

Detection of SARS‐CoV‐2 viral RNA by RT‐PCR assays is the primary diagnostic test for COVID‐19. Cycle threshold (C(T)) values generated by some of these assays provide inversely proportional proxy measurements of viral load. The clinical implications of C(T) values are incompletely characterized, particularly in solid organ transplant (SOT) recipients. We conducted a retrospective chart review of 25 adult SOT recipients admitted to the Yale New Haven Health System between March 1 and May 15, 2020, analyzing 50 test results to investigate the clinical implications of SARS‐CoV‐2 C(T) values in this population. Initial C(T) values from upper respiratory tract samples were significantly higher in patients on tacrolimus, but were not associated with admission severity nor highest clinical acuity. Viral RNA was detected up to 38 days from symptom onset with a gradual increase in C(T) values over time. In five patients with serial testing, C(T) values <35.0 were detected >21 days after symptom onset in 4/5 and ≥27 days in 2/5, demonstrating prolonged RNA detection. These data describe SARS‐CoV‐2 viral dynamics in SOT patients and suggest that C(T) values may not be useful to predict COVID‐19 severity in SOT patients. SARS‐CoV‐2 C(T) values may be more useful in informing infection prevention measures.

infections, such as influenza, C T values may correlate with disease severity. 1 In COVID-19, viral replication in upper respiratory tract specimens is highest between 0.6 days prior to symptom onset and 5 days after symptom onset before declining. 2, 3 As COVID-19 progresses, C T values increase in upper respiratory samples, reflecting diminished abundance of viral RNA with time. [2] [3] [4] [5] [6] [7] [8] Though C T values may reflect viral burden and time from initial viral acquisition, the utility of individual C T values for clinical decision-making or prognosis has not been established.

Solid organ transplant (SOT) recipients are generally at higher risk of acquiring infectious diseases and developing worse outcomes. While certain series of SOT recipients with COVID-19 report high overall disease severity and poor outcomes, 9, 10 lower C T are more likely to yield culturable, and therefore infectious, virus. [12] [13] [14] [15] Accordingly, we performed a retrospective study in a single health system to investigate the associations between initial SARS-CoV-2 C T values and clinical parameters in SOT patients as well as viral dynamics over time.

Adult (≥18 years old) SOT recipients on maintenance immunosuppression diagnosed with symptomatic COVID-19 and admitted to Yale New Haven Health System from March 1 to May 15, 2020 were identified by electronic chart review. Nasopharyngeal or combined nasopharyngeal and oropharyngeal samples were collected by medical professionals using flocked swabs in accordance with guidelines from the Centers for Disease Control and Prevention (CDC). Repeat testing was primarily performed for discharge to extended care facilities due to requirements of two negative SARS-CoV-2 RT-PCR assays before acceptance.

Patients with SARS-CoV-2 RT-PCR testing performed at the Yale New Haven Hospital clinical virology laboratory reported as detected, positive, presumptive positive, or inconclusive were included. SARS-CoV-2 RT-PCR was performed on nasopharyngeal or combined nasopharyngeal and oropharyngeal samples using a laboratory developed test (LDT) derived from the CDC assay and approved via an Emergency Use Authorization from the Food and Drug Administration, 16 or the commercially available Cepheid Xpert Xpress SARS-CoV-2 test (hereafter referred to as Xpert). 17 The LDT detects two SARS-CoV-2-specific regions of the viral nucleocapsid gene (N1 and N2) and the Xpert detects a pan-Sarbecovirus target in the envelope (E) or the SARS-CoV-2-specific N2 gene. Definitions of positive, inconclusive, and negative tests are provided in the Appendix S1. Evaluation of C T values was performed using N2 C T results after demonstrating assay results were comparable (Appendix S1). We grouped N2 C T into low (0-20.0), moderate (20.1-30. Clinical Improvement (WHO OSCI). 18 WHO OSCI scores used in this study are provided in the Appendix S1. This score was modified by adding one additional point if a patient was admitted to an intensive care unit (ICU). Patients with a modified WHO OSCI score ≥5 were designated as severe and those with a score of <5 were designated as non-severe. The highest clinical acuity as determined by the modified WHO OSCI score was used to categorize patients into non-severe or severe groups to investigate clinical associations.

This study was approved by the Yale Human Investigation Committee (IRB Protocol Identification 2000028099). 

We identified 25 hospitalized SOT recipients who met the inclusion criteria. Demographic and clinical data are presented in Table 1 . Some studies have demonstrated that SARS-CoV-2 could not be successfully cultured from clinical specimens with high C T values, particularly in those with C T values ≥33-35. 12 

We are grateful for statistical consultation provided by the Yale University StatLab.

The authors of this manuscript have no conflicts of interest to disclose as described by the American Journal of Transplantation.

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

David C. Gaston https://orcid.org/0000-0002-7320-5635

Maricar Malinis https://orcid.org/0000-0002-5720-9994

Marwan M. Azar https://orcid.org/0000-0001-5498-5042

A 5-year prospective multicenter evaluation of influenza infection in transplant recipients

SARS-CoV-2 viral load in upper respiratory specimens of infected patients

Temporal dynamics in viral shedding and transmissibility of COVID-19

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study

Quantitative detection and viral load analysis of SARS-CoV-2 in infected patients

Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China

Chronological changes of viral shedding in adult inpatients with COVID-19 in Wuhan, China

Viral dynamics in mild and severe cases of COVID-19

COVID-19 in elderly kidney transplant recipients

COVID-19 in solid organ transplant recipients: initial report from the US epicenter

COVID-19 in longterm liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy

Virological assessment of hospitalized patients with COVID-2019

Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards

Predicting infectious SARS-CoV-2 from diagnostic samples

Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19

Accelerated Emergency Use Authorization (EUA) Summary SARS-CoV-2 RT-PCR Assay

Xpert Xpress SARS-CoV-2 Instructions for Use, For Use Under an Emergency Use Authorization (EUA) Only

WHO R&D Blueprint novel Coronavirus COVID-19 Therapeutic Trial Synopsis Draft

First experience of SARS-CoV-2 infections in solid organ transplant recipients in the Swiss Transplant Cohort Study

In-depth virological assessment of kidney transplant recipients with COVID-19

Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506

COVID-19 and calcineurin inhibitors: should they get left out in the storm?

Coronavirus disease 2019 Pneumonia in immunosuppressed renal transplant recipients: a summary of 10 confirmed cases in Wuhan, China

Viral shedding prolongation in a kidney transplant patient with COVID-19 pneumonia

USA. Duration of Isolation Precautions for Adults with COVID-19

To interpret the SARS-CoV-2 test, consider the cycle threshold value

Disposition of patients with COVID-19 infection whose respiratory specimens remain SARS-CoV-2 PCR-positive

Comparative performance of SARS-CoV-2 detection assays using seven different primer-probe sets and one assay kit

College of American Pathologists (CAP) Microbiology Committee Perspective: caution must be used in interpreting the Cycle Threshold (Ct) value

Tocilizumab treatment for cytokine release syndrome in hospitalized COVID-19 patients: survival and clinical outcomes

Clinical implications of SARS-CoV-2 cycle threshold values in solid organ transplant recipients